Relevant Interviews, Disease and Trial Updates and Stock-Markets News posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Main focus: Next-generation iPSC-derived cell therapies
Company stage: Clinical
Diseases (gene editing): Solid tumours, haematological cancers
Genome editing tool: CRISPR
Funding stage: Public (NASDAQ:TCRR)
Location: Cambridge, MA, USA
Gene editing partnerships: Arbor Biotechnologies
TCR2 Therapeutics is developing next-generation cellular therapies to treat cancer. The company's technology is based on TCR Fusion Construct (TRuC) T cells that are engineered to recognise tumour cells. The company's engagement in the gene-editing space comes through its collaboration with Arbor Biotechnologies, giving TCR2 access to CRISPR-based gene-editing systems for the development of allogeneic cell therapies.